mRNA cancer immunotherapy - Med Pharma News

Graphic: mRNA cancer immunotherapy setback as BioNTech BNT113 misses its first endpoint, with overall survival still pending

mRNA Cancer Immunotherapy Setback: BNT113 Misses Endpoint

Megan Wood6 hours ago57 minutes ago011 mins

An mRNA cancer immunotherapy, BioNTech’s BNT113, missed its PFS goal in head and neck cancer. Overall survival is still being assessed. What it means.